Advertisement
BMY vs GSK
Which Stock Would AI Choose? Bristol-Myers Squibb (BMY) vs. GSK (GSK) Stock Comparison
Key Takeaways
- Bristol-Myers Squibb (BMY) and GSK (GSK) are major pharmaceutical companies with diversified portfolios spanning oncology, immunology, and vaccines.
- Over recent market activity, BMY has shown stronger year-to-date gains compared to GSK, while GSK delivered a solid first-quarter performance driven by specialty medicines.
- Both stocks offer attractive dividend yields, with BMY providing a higher yield amid its debt profile and GSK focusing on pipeline execution under new leadership.
- Sector exposure remains similar in healthcare, but BMY emphasizes immuno-oncology products like Opdivo, whereas GSK highlights respiratory and specialty growth drivers.
- Recent sentiment for BMY reflects anticipation around upcoming earnings, while GSK faced initial share pressure post-Q1 results due to one-time factors.
- Relative positioning shows trade-offs in growth stability versus dividend appeal for investors seeking pharmaceutical exposure.
Introduction
Bristol-Myers Squibb (BMY) and GSK (GSK) represent two established players in the global pharmaceutical sector, making their stocks relevant for comparison in the current market environment. Investors and traders focused on healthcare equities often evaluate these names for their dividend profiles, pipeline developments, and resilience amid regulatory and competitive pressures. This analysis examines recent performance, business models, and market positioning to highlight contrasts that may inform decisions for those constructing diversified portfolios or monitoring sector rotations. The comparison draws on verifiable data from financial platforms and company reports to provide an objective view suitable for both experienced market participants and those new to biopharma analysis.
BMY Overview and Recent Performance
Bristol-Myers Squibb (BMY) operates as a leading biopharmaceutical company with key products in oncology, hematology, immunology, and cardiovascular areas. Its portfolio includes established therapies such as Opdivo and Eliquis. In recent market activity, the stock has traded near the upper end of its 52-week range, reflecting positive momentum amid broader healthcare sector interest. Year-to-date returns have outpaced the S&P 500, supported by pipeline advancements including new trial initiations and regulatory updates. Sentiment has been influenced by anticipation of second-quarter results, with analysts noting expectations for earnings growth despite ongoing revenue dynamics from patent expirations. Broader factors such as industry-wide focus on immuno-oncology have contributed to relative stability in recent weeks.
GSK Overview and Recent Performance
GSK (GSK) is a global healthcare company with strengths in specialty medicines, vaccines, and general medicines, including respiratory products like Trelegy. The firm delivered a strong first-quarter performance with sales growth driven by specialty areas, though shares experienced volatility following the results due to concerns over one-time boosts. In recent market activity, the stock has posted solid longer-term gains, including over the past year, while trading in the middle of its range. Upcoming second-quarter results are scheduled soon, adding to investor focus on execution under current leadership. Sentiment has been shaped by pipeline progress in areas such as oncology and vaccines, alongside macroeconomic influences on the broader FTSE 100. Overall positioning reflects a balance of growth drivers and cost management efforts.
Trending AI Robots
Tickeron maintains a curated Trending AI Robots page that highlights select AI trading bots optimized for prevailing market conditions. While hundreds of AI trading bots are available across thousands of tickers, only those demonstrating the strongest alignment with current trends, risk parameters, and performance metrics earn placement in this section. Available bots span diverse trading styles, strategies, timeframes, and statistical profiles, with historical performance data often showing ranges from modest single-digit returns in conservative setups to higher figures in more aggressive configurations, depending on market volatility and ticker selection. This variety allows users to explore options suited to different objectives. For more details on the latest trending selections, visit Trending AI Robots.
Head-to-Head Comparison
In business model terms, Bristol-Myers Squibb (BMY) maintains a heavier concentration in oncology and specialty therapies, while GSK (GSK) balances specialty medicines with a notable vaccines and respiratory presence. Growth drivers differ accordingly, with BMY tied to immuno-oncology expansions and GSK emphasizing specialty sales momentum alongside pipeline acceleration. Recent momentum has favored BMY on a year-to-date basis, contrasting with GSK’s stronger one-year total return profile. Risk factors include BMY’s elevated leverage compared to GSK’s more measured debt levels, alongside shared exposure to regulatory approvals and competition. Sector exposure is comparable within healthcare, though market sentiment has shown GSK shares reacting more sharply to earnings nuances in recent periods. Trade-offs emerge in dividend sustainability versus potential for pipeline-driven upside, depending on investor time horizons and risk tolerance.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings visibility, and relative positioning in recent market activity, Tickeron’s AI models would currently assign a modest probabilistic edge to Bristol-Myers Squibb (BMY) due to steadier year-to-date performance and pipeline catalysts. GSK (GSK) remains competitive on longer-term returns and growth execution. This assessment reflects data patterns rather than guarantees, as market conditions can shift with new developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a StrongBuy and GSK is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 3 FA rating(s) are green whileGSK’s FA Score has 1 green FA rating(s).
- BMY’s FA Score: 3 green, 2 red.
- GSK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 6 TA indicator(s) are bullish while GSK’s TA Score has 5 bullish TA indicator(s).
- BMY’s TA Score: 6 bullish, 3 bearish.
- GSK’s TA Score: 5 bullish, 4 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а +5.19% price change this week, while GSK (@Pharmaceuticals: Major) price change was +0.66% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.41%. For the same industry, the average monthly price growth was -2.13%, and the average quarterly price growth was +3.17%.
Reported Earning Dates
BMY is expected to report earnings on Oct 29, 2026.
GSK is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-1.41% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| BMY | GSK | BMY / GSK | |
| Capitalization | 133B | 104B | 128% |
| EBITDA | 15B | 10.1B | 149% |
| Gain YTD | 25.170 | 7.222 | 349% |
| P/E Ratio | 14.39 | 16.41 | 88% |
| Revenue | 48.5B | 32.8B | 148% |
| Total Cash | N/A | 3.44B | - |
| Total Debt | 46.4B | 19.1B | 243% |
BMY | GSK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 35 | 64 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | 78 Overvalued | |
PROFIT vs RISK RATING 1..100 | 79 | 42 | |
SMR RATING 1..100 | 25 | 27 | |
PRICE GROWTH RATING 1..100 | 19 | 48 | |
P/E GROWTH RATING 1..100 | 69 | 53 | |
SEASONALITY SCORE 1..100 | 50 | 55 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BMY's Valuation (3) in the Pharmaceuticals Major industry is significantly better than the same rating for GSK (78). This means that BMY’s stock grew significantly faster than GSK’s over the last 12 months.
GSK's Profit vs Risk Rating (42) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (79). This means that GSK’s stock grew somewhat faster than BMY’s over the last 12 months.
BMY's SMR Rating (25) in the Pharmaceuticals Major industry is in the same range as GSK (27). This means that BMY’s stock grew similarly to GSK’s over the last 12 months.
BMY's Price Growth Rating (19) in the Pharmaceuticals Major industry is in the same range as GSK (48). This means that BMY’s stock grew similarly to GSK’s over the last 12 months.
GSK's P/E Growth Rating (53) in the Pharmaceuticals Major industry is in the same range as BMY (69). This means that GSK’s stock grew similarly to BMY’s over the last 12 months.
| BMY | GSK | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 42% | N/A |
| Stochastic ODDS (%) | 2 days ago 53% | 1 day ago 63% |
| Momentum ODDS (%) | 2 days ago 60% | 1 day ago 44% |
| MACD ODDS (%) | 3 days ago 67% | 1 day ago 73% |
| TrendWeek ODDS (%) | 2 days ago 54% | 1 day ago 64% |
| TrendMonth ODDS (%) | 2 days ago 57% | 1 day ago 49% |
| Advances ODDS (%) | 4 days ago 54% | 4 days ago 62% |
| Declines ODDS (%) | about 1 month ago 55% | 1 day ago 54% |
| BollingerBands ODDS (%) | 2 days ago 51% | 1 day ago 48% |
| Aroon ODDS (%) | 2 days ago 67% | 1 day ago 55% |
Advertisement
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.